Regeneron Pharmaceuticals, Inc… (NASDAQ:REGN)

Bull and Bear

Top Analyst Upgrades and Downgrades: Control4, Cree, NetApp, Twitter, Yahoo!, Yelp and More

Stocks are trying to recover from their recent selling pressure, but investors remain wary. These same investors are caught between a rock and a hard place -- they want upside, ...
Read Full Story »
research

Credit Suisse Says Grit Your Teeth and Buy Biotech

For the second time since late February, a huge run on the momentum, and specifically biotech, names hit the market last week. Again, the biotech benchmark took a huge 4% ...
Read Full Story »
Morgan Stanley logo

Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks

Like many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage of ...
Read Full Story »
West side view of the United States Capitol building.

Top Biotechnology Stocks On Sale Again

For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress over drug pricing concerns hit the ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Baker Hughes, Cameron, Cisco, Facebook, VeriSign and More

Stocks have retreated from their highs, and investors still want upside from the market while avoiding the next major sell-off. 24/7 Wall St. reviews many analyst research reports each morning ...
Read Full Story »
investing

Piper Jaffray Stocks to Buy for S&P 500 Going to 2,100

As the bull market enters its sixth year, the S&P 500 continues to set new highs and intermediate-term measures of market strength have turned positive since February. The old Wall ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Angie’s List, Itron, NVIDIA, Regeneron, Sempra, More

Earnings season is winding down and the markets are proving to be volatile so far in 2014. Analysts and investors alike are trying to adjust their expectations for 2014 to ...
Read Full Story »
Monkey evil

Top Analyst Upgrades and Downgrades: Amazon, Control4, Ocwen, Sprint, Veeco, More

Earnings season is winding down and stocks are trying to recover from the sell-off and volatility. Investors and analysts alike are now adjusting their portfolios and expectations for 2014. Each ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Intel, ExOne, GameStop, SodaStream and More

Earnings season is getting off to a start and analysts are still making many changes to their 2014 outlooks. Investors are still positioning their portfolios for 2014 at the same ...
Read Full Story »
yoga

Ten Top Growth Stock Ideas for 2014 From Baird

Many of the top Wall Street firms released their top 2014 ideas in the month of December. This is the first full trading week of 2014, and many firms are ...
Read Full Story »
Palo Alto_hero

Piper Jaffray Top Stocks to Buy for 2014

Like most firms that we cover on Wall Street, Piper Jaffray has updated its top names to buy for 2014, and the firm has an extensive market commentary to go ...
Read Full Story »
biotech

Credit Suisse Offers Top Biotech Stocks to Buy for 2014

Credit Suisse is out and pounding the table that biotechnology cannot be ignored in 2014. Biotech has been the top-performing sector for the past three years, with year-to-date performance up ...
Read Full Story »
biotech

Solid Biotech Stocks With the Best Revenue Growth for 2014

Any time investors look for companies growing sales the most, one area that almost always stands out is the up and coming biotech stocks. After all, sales can grow from ...
Read Full Story »
Bank

UBS Sees Hedge Funds Selling Health Care and Buying Financial and Energy Stocks

The UBS proprietary institutional flow data indicates that hedge funds are increasing exposure to financials and decreasing exposure to health care. Given that health care has outperformed significantly year to ...
Read Full Story »
biotech

Market Take: Biotech Suffers Under Government Shutdown Too!

The field of pharmaceuticals is very well established and often is considered to be a very defensive sector. As such, investors flock to the drug sector in times of uncertainty. ...
Read Full Story »